Radiation

New Way to Do PET Scans

  There’s a better way to do a PET scan, by using radiotracer fluciclovine (fluorine-18; F-18) (Journal of Nuclear Medicine, March 2017) According to researcher Ashesh B. Jani, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, fluciclovine can improve imaging in recurrent prostate cancer patients with no additional radiation side effects. An improved PET scan helps patients and doctors see if their advanced stage targeted treatment is working.   For the study, 96 patients were enrolled in a clinical trial of radiotherapy for recurrent prostate cancer after prostatectomy. All patients underwent initial treatment planning based on results from conventional [...]

By | March 6th, 2017|Advanced Prostate Cancer, Imaging, NaF-PET/CT, Radiation|0 Comments

Men Who Fail Primary Radiation Can Have Good Results After Salvage Surgery

Men who have decided to have radiation as their first (primary) treatment for prostate cancer have a one-third chance of recurrence. Some of those men have salvage radical prostatectomy (SRP)  to fight the recurrence.  A study shows this might be a good idea. Antoni Vilaseca, MD, etal from Memorial Sloan-Kettering Cancer Center in New York, studied 251 men who had a Salvage Radical Prostatectomy (SRP) after they failed their primary treatment with external beam radiation therapy, brachytherapy (seeds), or with both. The researchers evaluated long-term oncologic outcomes (survival and disease progression) of the SRP in general as well as evaluating if using minimally [...]

Expanding the Role of Radium-223 (Xofigo)

One of the newer drugs and one that has recently had great air play is the bone targeting radiopharmaceutical drug radium-223 or Xofigo. Currently, it is approved for men with castrate resistant prostate cancer with bone metastases. The problem is that currently Xofigo is only approved for one round of treatment using 6 monthly infusions. Given its success, the question we are now asking is if additional dosing would provide an even better result? Bayer Pharmaceuticals currently has a number of clinical trials examining this type of question. In one of the small prospective studies looking at the impact of [...]

A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer

Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs.   We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate cancer is a very strong negative prognostic indicator. Prostate cancer’s tendency to favor bone over soft tissue causes significant morbidity and mortality for men. Bone metastasis has a major impact on quality of life and longevity for men with prostate cancer and it needs to be aggressively treated. Because of this, prostate cancer survivors need to focus on drugs that slow down or interfere with [...]